CD86 and cancer: Furthermore, analysis of immune checkpoint ligand expression of cancer cells alone revealed no difference in the frequency of cells expressing PD‐L1, CD86, GAL‐9 or VISTA (Figure 4A‐C) or PD‐L2, CD80, HLA‐DR or PVR (Figure S2) in the presence of PRAME.